Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
Public ClinicalTrials.gov record NCT06333015. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Multicenter, Randomized, Controlled Clinical Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research study is evaluating the safety and efficacy (performance) of the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens (IOL) in subjects who receive this IOL in both eyes.
Study identification
- NCT ID
- NCT06333015
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 304 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 22 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 7, 2024 (Actual)
- Primary completion
- Jun 11, 2026 (Actual)
- Completion
- Jun 11, 2026 (Actual)
- Last update posted
- Jul 13, 2026
2024 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 119 | Dothan | Alabama | 36301 | — |
| Site 108 | Northridge | California | 91325 | — |
| Site 116 | Alexandria | Minnesota | 56308 | — |
| Site 107 | Bloomington | Minnesota | 55420 | — |
| Site 101 | Omaha | Nebraska | 68137 | — |
| Site 109 | Las Vegas | Nevada | 89145 | — |
| Site 113 | Garden City | New York | 11530 | — |
| Site 118 | West Fargo | North Dakota | 58078 | — |
| Site 102 | Brecksville | Ohio | 44141 | — |
| Site 105 | North Charleston | South Carolina | 29406 | — |
| Site 106 | Sioux Falls | South Dakota | 57108 | — |
| Site 103 | Dallas | Texas | 75243 | — |
| Site 117 | San Antonio | Texas | 78209 | — |
| Site 112 | San Antonio | Texas | 78229 | — |
| Site 115 | Sugar Land | Texas | 77478 | — |
| Site 111 | Mount Pleasant | Wisconsin | 53405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06333015, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 13, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06333015 live on ClinicalTrials.gov.